科研动态期刊摘要

普瑞巴林:缩减一种平庸镇痛药的理由

The BMJ · 2026-11-12

摘要

自2005年商业上市以来,普瑞巴林已在全球创造超过500亿美元(370亿英镑;440亿欧元)的收入。它最初作为抗惊厥药开发,主要通过用于疼痛治疗而成为“重磅炸弹”药物,包括糖尿病神经病变、带状疱疹后神经痛、纤维肌痛和腰痛。然而,在其商业成功的背后,却有一个不那么光彩的故事:越来越多的证据表明其危害,从水肿和体重增加到处方戒断、滥用和死亡。在一项关联研究中,Cairns及其同事(10.1136/bmj-2026-101021)考察了澳大利亚涉及普瑞巴林的处方模式和过量用药趋势。1 他们利用九年的配药索赔和中毒中心数据,评估了监管干预(包括更严格的处方限制、加强的安全

English
Pregabalin: the case for dialling back on a mediocre analgesic

Since its commercial launch in 2005, pregabalin has generated more than $50bn (£37bn; €44bn) in global revenue. Originally developed as an anticonvulsant, it became a “blockbuster” largely through its use for pain, including diabetic neuropathy, postherpetic neuralgia, fibromyalgia, and low back pain. Yet behind its commercial success lies a less flattering story: mounting evidence of harms ranging from oedema and weight gain to withdrawal, misuse, and death.In a linked study, Cairns and colleagues (10.1136/bmj-2026-101021) examine prescribing patterns and overdose trends involving pregabalin in Australia.1 Drawing on nine years of dispensing claims and poison centre data, they assessed changes following regulatory interventions (including tighter prescribing restrictions, strengthened saf

内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界